New York, NY -- (SBWIRE) -- 01/02/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: BIOLASE Inc (NASDAQ:BIOL), AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Atlantic Power Corp (NYSE:AT)
BIOLASE Inc (NASDAQ:BIOL) showed a volume of 1.26 million shares by the end of last trade whereas the average volume of the stock remained 501,508.00 shares. The stock opened the session at $3.04 but then moved to $2.83. At that price, the stock showed a negative performance of -7.52%. BIOLASE, Inc., formerly BIOLASE Technology, Inc. is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine. The Company's dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications in a minimally invasive manner.
Will BIOL Get Buyers Even After The Recent Rally? Find Out Here
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) opened the session at $1.37 and closed the session at $1.38. The stock showed a negative performance of -1.43% in previous trading session. Traded with volume of 1.25 million shares in the prior session and the average volume of the stock remained 2.69 million shares. Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer.
Has AEZS Found The Bottom And Ready To Gain Momentum? Find Out Here
Synta Pharmaceuticals Corp (NASDAQ:SNTA) opened the session at $5.10 and closed the session at $5.24. The stock showed a positive performance of 3.35% in previous trading session. Traded with volume of 1.25 million shares in the prior session and the average volume of the stock remained 2.09 million shares. The beta of the stock remained 3.09. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. Its drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine. During the year ended December 31, 2011,
Why Should Investors Buy SNTA After The Recent Gain? Just Go Here and Find Out
Atlantic Power Corp (NYSE:AT) the stock advanced 1.75% and finished the session at $3.48. Traded with volume of 1.24 million shares in the prior session and the average volume of the stock remained 1.39 million shares. The beta of the stock remained 0.42. Atlantic Power Corporation (Atlantic Power) owns and operates a fleet of power generation and infrastructure assets in the United States and Canada. The Company’s power generation projects sell electricity to utilities and industrial customers under long-term power purchase agreements. During the year ended December 31, 2011, its power generation projects in operation had an aggregate gross electric generation capacity of approximately 3,397 megawatts in which its ownership interest was approximately 2,140 megawatts.
Will AT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)